About In8bio Company
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients With Newly Diagnosed Glioblastoma
IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies, presented data demonstrating that all patients treated with INB-
12 Health Care Stocks Moving In Friday's After-Market Session
GainersForte Biosciences (NASDAQ:FBRX) shares increased by 11.8% to $0.5 during Friday's after-market session. Today's trading volume for this security ended up closing at 287.3K shares, which is 905.
Promising Future for IN8bio: Anticipated Data Presentations, Capital Raise, and Innovative Developments